Top

Published in:

01-03-2019 | Review Article

Asymptomatic and normocalcemic hyperparathyroidism, the silent attack: a combo-endocrinology overview

Authors: Dimitrios A. Anastasilakis, Polyzois Makras, Stergios A. Polyzos, Athanasios D. Anastasilakis, Part of the COMBO ENDO TEAM: 2017

Published in: Hormones | Issue 1/2019

Abstract

Asymptomatic primary hyperparathyroidism (PHPT) and the new variant of PHPT, normocalcemic PHPT, are considered by many physicians as mild, innocuous forms of disease, requiring nothing more than monitoring. Although this may be true in some cases in which the disease does not progress or cause complications, deterioration with more or less severe manifestations may occur. In the present review, we discuss the existing evidence of both the classic (skeletal and renal) and non-classic (cardiovascular, gastrointestinal, and psychiatric) features that have been attributed to asymptomatic and normocalcemic PHPT and the treatment effect on them.

Bilezikian JP, Khan AA, Potts JT Jr (2009) Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J Clin Endocrinol Metab 94:335–339CrossRefPubMedPubMedCentral

Lowe H, McMahon DJ, Rubin MR, Bilezikian JP, Silverberg SJ (2007) Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype. J Clin Endocrinol Metab 92:3001–3005CrossRefPubMed

Silverberg SJ, Bilezikian JP (2003) “Incipient” primary hyperparathyroidism: a “forme fruste” of an old disease. J Clin Endocrinol Metab 88:5348–5352CrossRefPubMed

Silverberg SJ, Lewiecki EM, Mosekilde L, Peacock M, Rubin MR (2009) Presentation of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab 94:351–365CrossRefPubMedPubMedCentral

Cusano NE, Maalouf NM, Wang PY, Zhang C, Cremers SC, Haney EM et al (2013) Normocalcemic hyperparathyroidism and hypoparathyroidism in two community-based nonreferral populations. J Clin Endocrinol Metab 98:2734–2741CrossRefPubMedPubMedCentral

Maruani G, Hertig A, Paillard M, Houillier P (2003) Normocalcemic primary hyperparathyroidism: evidence for a generalized target-tissue resistance to parathyroid hormone. J Clin Endocrinol Metab 88:4641–4648CrossRefPubMed

Khan AA, Hanley DA, Rizzoli R, Bollerslev J, Young JE, Rejnmark L et al (2017) Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus. Osteoporosis International : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 28:1–19CrossRef

Eastell R, Brandi ML, Costa AG, D'Amour P, Shoback DM, Thakker RV (2014) Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab 99:3570–3579CrossRefPubMed

Cromer MK, Starker LF, Choi M, Udelsman R, Nelson-Williams C, Lifton RP et al (2012) Identification of somatic mutations in parathyroid tumors using whole-exome sequencing. J Clin Endocrinol Metab 97:E1774–E1781CrossRefPubMedPubMedCentral

10.

Bilezikian JP, Brandi ML, Eastell R, Silverberg SJ, Udelsman R, Marcocci C et al (2014) Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endocrinol Metab 99:3561–3569CrossRefPubMedPubMedCentral

11.

Makras P, Anastasilakis AD (2018) Bone disease in primary hyperparathyroidism. Metabolism 80:57–65CrossRefPubMed

12.

Christiansen P, Steiniche T, Brixen K, Hessov I, Melsen F, Charles P et al (1997) Primary hyperparathyroidism: biochemical markers and bone mineral density at multiple skeletal sites in Danish patients. Bone 21:93–99CrossRefPubMed

13.

Rubin MR, Bilezikian JP, McMahon DJ, Jacobs T, Shane E, Siris E et al (2008) The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. J Clin Endocrinol Metab 93:3462–3470CrossRefPubMedPubMedCentral

14.

Cipriani C, Biamonte F, Costa AG, Zhang C, Biondi P, Diacinti D et al (2015) Prevalence of kidney stones and vertebral fractures in primary hyperparathyroidism using imaging technology. J Clin Endocrinol Metab 100:1309–1315CrossRefPubMedPubMedCentral

15.

Walker MD, Silverberg SJ (2018) Primary hyperparathyroidism. Nat Rev Endocrinol 14:115–125CrossRefPubMed

16.

Amaral LM, Queiroz DC, Marques TF, Mendes M, Bandeira F (2012) Normocalcemic versus hypercalcemic primary hyperparathyroidism: more stone than bone? J Osteoporos 2012:128352CrossRefPubMedPubMedCentral

17.

Tay YD, Liu M, Bandeira L, Bucovsky M, Lee JA, Silverberg SJ et al (2018) Occult urolithiasis in asymptomatic primary hyperparathyroidism. Endocr Res 43:106–115CrossRefPubMedPubMedCentral

18.

Yu N, Donnan PT, Leese GP (2011) A record linkage study of outcomes in patients with mild primary hyperparathyroidism: the Parathyroid Epidemiology and Audit Research Study (PEARS). Clin Endocrinol 75:169–176CrossRef

19.

Walker MD, Silverberg SJ (2008) Cardiovascular aspects of primary hyperparathyroidism. J Endocrinol Investig 31:925–931CrossRef

20.

Aktas Yilmaz B, Akyel A, Kan E, Ercin U, Tavil Y, Bilgihan A et al (2013) Cardiac structure and functions in patients with asymptomatic primary hyperparathyroidism. J Endocrinol Investig 36:848–852

21.

Ambrogini E, Cetani F, Cianferotti L, Vignali E, Banti C, Viccica G et al (2007) Surgery or surveillance for mild asymptomatic primary hyperparathyroidism: a prospective, randomized clinical trial. J Clin Endocrinol Metab 92:3114–3121CrossRefPubMed

22.

Bollerslev J, Jansson S, Mollerup CL, Nordenstrom J, Lundgren E, Torring O et al (2007) Medical observation, compared with parathyroidectomy, for asymptomatic primary hyperparathyroidism: a prospective, randomized trial. J Clin Endocrinol Metab 92:1687–1692CrossRefPubMed

23.

Rao DS, Phillips ER, Divine GW, Talpos GB (2004) Randomized controlled clinical trial of surgery versus no surgery in patients with mild asymptomatic primary hyperparathyroidism. J Clin Endocrinol Metab 89:5415–5422CrossRefPubMed

24.

Eller-Vainicher C, Filopanti M, Palmieri S, Ulivieri FM, Morelli V, Zhukouskaya VV et al (2013) Bone quality, as measured by trabecular bone score, in patients with primary hyperparathyroidism. Eur J Endocrinol 169:155–162CrossRefPubMed

25.

Hansen S, Hauge EM, Rasmussen L, Jensen JE, Brixen K (2012) Parathyroidectomy improves bone geometry and microarchitecture in female patients with primary hyperparathyroidism: a one-year prospective controlled study using high-resolution peripheral quantitative computed tomography. J Bone Miner Res 27:1150–1158CrossRefPubMed

26.

Lundstam K, Heck A, Mollerup C, Godang K, Baranowski M, Pernow Y et al (2015) Effects of parathyroidectomy versus observation on the development of vertebral fractures in mild primary hyperparathyroidism. J Clin Endocrinol Metab 100:1359–1367CrossRefPubMed

27.

Lundstam K, Heck A, Godang K, Mollerup C, Baranowski M, Pernow Y et al (2017) Effect of surgery versus observation: skeletal 5-year outcomes in a randomized trial of patients with primary HPT (the SIPH study). J Bone Miner Res 32:1907–1914CrossRefPubMed

28.

Khosla S, Melton LJ 3rd, Wermers RA, Crowson CS, O'Fallon W, Riggs B (1999) Primary hyperparathyroidism and the risk of fracture: a population-based study. J Bone Miner Res 14:1700–1707CrossRefPubMed

29.

Zanocco KA, Wu JX, Yeh MW (2017) Parathyroidectomy for asymptomatic primary hyperparathyroidism: a revised cost-effectiveness analysis incorporating fracture risk reduction. Surgery 161:16–24CrossRefPubMed

30.

Rejnmark L, Vestergaard P, Mosekilde L (2011) Nephrolithiasis and renal calcifications in primary hyperparathyroidism. J Clin Endocrinol Metab 96:2377–2385CrossRefPubMed

31.

Iwata S, Walker MD, Di Tullio MR, Hyodo E, Jin Z, Liu R et al (2012) Aortic valve calcification in mild primary hyperparathyroidism. J Clin Endocrinol Metab 97:132–137CrossRefPubMed

32.

Walker MD, Rundek T, Homma S, DiTullio M, Iwata S, Lee JA et al (2012) Effect of parathyroidectomy on subclinical cardiovascular disease in mild primary hyperparathyroidism. Eur J Endocrinol 167:277–285CrossRefPubMedPubMedCentral

33.

Farahnak P, Ring M, Caidahl K, Farnebo LO, Eriksson MJ, Nilsson IL (2010) Cardiac function in mild primary hyperparathyroidism and the outcome after parathyroidectomy. Eur J Endocrinol 163:461–467CrossRefPubMedPubMedCentral

34.

Nilsson IL, Aberg J, Rastad J, Lind L (1999) Endothelial vasodilatory dysfunction in primary hyperparathyroidism is reversed after parathyroidectomy. Surgery 126:1049–1055CrossRefPubMed

35.

McMahon DJ, Carrelli A, Palmeri N, Zhang C, DiTullio M, Silverberg SJ et al (2015) Effect of parathyroidectomy upon left ventricular mass in primary hyperparathyroidism: a meta-analysis. J Clin Endocrinol Metab 100:4399–4407CrossRefPubMedPubMedCentral

36.

Talpos GB, Bone HG 3rd, Kleerekoper M, Phillips ER, Alam M, Honasoge M et al (2000) Randomized trial of parathyroidectomy in mild asymptomatic primary hyperparathyroidism: patient description and effects on the SF-36 health survey. Surgery 128:1013–1020 discussion 20–1CrossRefPubMed

37.

Espiritu RP, Kearns AE, Vickers KS, Grant C, Ryu E, Wermers RA (2011) Depression in primary hyperparathyroidism: prevalence and benefit of surgery. J Clin Endocrinol Metab 96:E1737–E1745CrossRefPubMed

38.

Kahal H, Aye M, Rigby AS, Sathyapalan T, England RJ, Atkin SL (2012) The effect of parathyroidectomy on neuropsychological symptoms and biochemical parameters in patients with asymptomatic primary hyperparathyroidism. Clin Endocrinol 76:196–200CrossRef

39.

Walker MD, McMahon DJ, Inabnet WB, Lazar RM, Brown I, Vardy S et al (2009) Neuropsychological features in primary hyperparathyroidism: a prospective study. J Clin Endocrinol Metab 94:1951–1958CrossRefPubMedPubMedCentral

40.

Roman SA, Sosa JA, Pietrzak RH, Snyder PJ, Thomas DC, Udelsman R et al (2011) The effects of serum calcium and parathyroid hormone changes on psychological and cognitive function in patients undergoing parathyroidectomy for primary hyperparathyroidism. Ann Surg 253:131–137CrossRefPubMed

41.

Tsvetov G, Hirsch D, Shimon I, Benbassat C, Masri-Iraqi H, Gorshtein A et al (2017) Thiazide treatment in primary hyperparathyroidism-a new indication for an old medication? J Clin Endocrinol Metab 102:1270–1276PubMed

42.

Eller-Vainicher C, Palmieri S, Cairoli E, Goggi G, Scillitani A, Arosio M et al (2018) Protective effect of denosumab on bone in older women with primary hyperparathyroidism. J Am Geriatr Soc 66:518–524CrossRefPubMed

43.

Somnay YR, Craven M, McCoy KL, Carty SE, Wang TS, Greenberg CC et al (2017) Improving diagnostic recognition of primary hyperparathyroidism with machine learning. Surgery 161:1113–1121CrossRefPubMed

44.

Tuna MM, Caliskan M, Unal M, Demirci T, Dogan BA, Kucukler K et al (2016) Normocalcemic hyperparathyroidism is associated with complications similar to those of hypercalcemic hyperparathyroidism. J Bone Miner Metab 34:331–335CrossRefPubMed

45.

Koumakis E, Souberbielle JC, Sarfati E, Meunier M, Maury E, Gallimard E et al (2013) Bone mineral density evolution after successful parathyroidectomy in patients with normocalcemic primary hyperparathyroidism. J Clin Endocrinol Metab 98:3213–3220CrossRefPubMed

46.

Mokrysheva N, Mirnaya S, Eremkina A, Krupinova J, Kovaleva E (2017) Normocalcemic versus hypercalcemic primary hyperparathyroidism: a comparative study. Endocr Abstr 49:EP257

47.

Chen G, Xue Y, Zhang Q, Xue T, Yao J, Huang H et al (2015) Is normocalcemic primary hyperparathyroidism harmful or harmless? J Clin Endocrinol Metab 100:2420–2424CrossRefPubMed

48.

Yu N, Leese GP, Donnan PT (2013) What predicts adverse outcomes in untreated primary hyperparathyroidism? The Parathyroid Epidemiology and Audit Research Study (PEARS). Clin Endocrinol 79:27–34CrossRef

49.

Andersson P, Rydberg E, Willenheimer R (2004) Primary hyperparathyroidism and heart disease--a review. Eur Heart J 25:1776–1787CrossRefPubMed

50.

Kontogeorgos G, Trimpou P, Laine CM, Olerod G, Lindahl A, Landin-Wilhelmsen K (2015) Normocalcaemic, vitamin D-sufficient hyperparathyroidism - high prevalence and low morbidity in the general population: a long-term follow-up study, the WHO MONICA project, Gothenburg, Sweden. Clin Endocrinol 83:277–284CrossRef

51.

Suh JM, Cronan JJ, Monchik JM (2008) Primary hyperparathyroidism: is there an increased prevalence of renal stone disease? AJR Am J Roentgenol 191:908–911CrossRefPubMed

Title: Asymptomatic and normocalcemic hyperparathyroidism, the silent attack: a combo-endocrinology overview
Authors: Dimitrios A. Anastasilakis
Polyzois Makras
Stergios A. Polyzos
Athanasios D. Anastasilakis
Part of the COMBO ENDO TEAM: 2017
Publication date: 01-03-2019
Publisher: Springer International Publishing
Published in: Hormones / Issue 1/2019
Print ISSN: 1109-3099
Electronic ISSN: 2520-8721
DOI: https://doi.org/10.1007/s42000-018-0069-6

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2019

Metabolic syndrome: joint diagnostic criteria and links with comorbidities

Triple A syndrome: two siblings with a novel mutation in the AAAS gene

Patient empowerment and the Mediterranean diet as a possible tool to tackle prediabetes associated with overweight or obesity: a pilot study

Vitamin D basis of Alzheimer’s disease: from genetics to biomarkers

Reviews based on 1st Mediterranean Experts Meeting on the topic “Vitamin D in the prevention of health disparities during adult life”

Correction to: Transsphenoidal surgery for pituitary adenomas: early results from a single center

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials